Thomas J Moore

Summary

Affiliation: Institute for Safe Medication Practices
Country: USA

Publications

  1. ncbi request reprint The Harms of Antipsychotic Drugs: Evidence from Key Studies
    Thomas J Moore
    Institute for Safe Medication Practices, 101 N Columbus St, Suite 410, Alexandria, VA, 22314, USA
    Drug Saf . 2016
  2. doi request reprint Electronic Health Data for Postmarket Surveillance: A Vision Not Realized
    Thomas J Moore
    Institute for Safe Medication Practices, 101 N Columbus St, Suite 410, Alexandria, VA, 22214, USA
    Drug Saf 38:601-10. 2015
  3. pmc Suicidal behavior and depression in smoking cessation treatments
    Thomas J Moore
    Institute for Safe Medication Practices, Alexandria, Virginia, United States of America
    PLoS ONE 6:e27016. 2011
  4. ncbi request reprint Serious adverse drug events reported to the Food and Drug Administration, 1998-2005
    Thomas J Moore
    Institute for Safe Medication Practices, 1800 Byberry Rd, Ste 810, Huntingdon Valley, PA 19006, USA
    Arch Intern Med 167:1752-9. 2007
  5. doi request reprint Thoughts and acts of aggression/violence toward others reported in association with varenicline
    Thomas J Moore
    Institute for Safe Medication Practices, Horsham, PA, USA
    Ann Pharmacother 44:1389-94. 2010
  6. pmc Prescription drugs associated with reports of violence towards others
    Thomas J Moore
    Institute for Safe Medication Practices, Alexandria, Virginia, United States of America
    PLoS ONE 5:e15337. 2010
  7. ncbi request reprint Reported medication errors associated with methotrexate
    Thomas J Moore
    Drug Safety and Policy, Institute for Safe Medication Practices, Huntingdon Valley, PA 19006, USA
    Am J Health Syst Pharm 61:1380-4. 2004
  8. ncbi request reprint Reported adverse event cases of methemoglobinemia associated with benzocaine products
    Thomas J Moore
    Institute for Safe Medication Practices, Huntingdon Valley, PA, USA
    Arch Intern Med 164:1192-6. 2004
  9. doi request reprint Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014
    Thomas J Moore
    Institute for Safe Medication Practices, Horsham, PA, USA
    Pharmacoepidemiol Drug Saf 25:713-8. 2016
  10. doi request reprint Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008
    Thomas J Moore
    Institute for Safe Medication Practices, Alexandria, Virginia2Department of Epidemiology and Biostatistics, The George Washington University School of Public Health and Health Services, Washington, DC
    JAMA Intern Med 174:90-5. 2014

Collaborators

Detail Information

Publications14

  1. ncbi request reprint The Harms of Antipsychotic Drugs: Evidence from Key Studies
    Thomas J Moore
    Institute for Safe Medication Practices, 101 N Columbus St, Suite 410, Alexandria, VA, 22314, USA
    Drug Saf . 2016
    ..The extent of injury to and impairment of multiple body systems caused by antipsychotic drugs shows the need for a scientific, clinical, and regulatory reappraisal of the appropriate use of these agents...
  2. doi request reprint Electronic Health Data for Postmarket Surveillance: A Vision Not Realized
    Thomas J Moore
    Institute for Safe Medication Practices, 101 N Columbus St, Suite 410, Alexandria, VA, 22214, USA
    Drug Saf 38:601-10. 2015
    ..Substantial investment and careful thinking is needed to improve the reliability of risk assessments based on electronic health data, and current limitations need to be fully understood. ..
  3. pmc Suicidal behavior and depression in smoking cessation treatments
    Thomas J Moore
    Institute for Safe Medication Practices, Alexandria, Virginia, United States of America
    PLoS ONE 6:e27016. 2011
    ..However, some epidemiological studies report an increased risk in smoking or smoking cessation independent of treatment, and differences between drugs are unknown...
  4. ncbi request reprint Serious adverse drug events reported to the Food and Drug Administration, 1998-2005
    Thomas J Moore
    Institute for Safe Medication Practices, 1800 Byberry Rd, Ste 810, Huntingdon Valley, PA 19006, USA
    Arch Intern Med 167:1752-9. 2007
    ..The US Food and Drug Administration has operated the Adverse Event Reporting System since 1998. It collects all voluntary reports of adverse drug events submitted directly to the agency or through drug manufacturers...
  5. doi request reprint Thoughts and acts of aggression/violence toward others reported in association with varenicline
    Thomas J Moore
    Institute for Safe Medication Practices, Horsham, PA, USA
    Ann Pharmacother 44:1389-94. 2010
    ..Thoughts and acts of aggression/violence toward others have been reported in postmarketing surveillance of varenicline, an aid to smoking cessation...
  6. pmc Prescription drugs associated with reports of violence towards others
    Thomas J Moore
    Institute for Safe Medication Practices, Alexandria, Virginia, United States of America
    PLoS ONE 5:e15337. 2010
    ..Violence towards others is a seldom-studied adverse drug event and an atypical one because the risk of injury extends to others...
  7. ncbi request reprint Reported medication errors associated with methotrexate
    Thomas J Moore
    Drug Safety and Policy, Institute for Safe Medication Practices, Huntingdon Valley, PA 19006, USA
    Am J Health Syst Pharm 61:1380-4. 2004
    ..Medication errors reported to FDA as adverse events in which methotrexate was identified as a possible contributor were studied...
  8. ncbi request reprint Reported adverse event cases of methemoglobinemia associated with benzocaine products
    Thomas J Moore
    Institute for Safe Medication Practices, Huntingdon Valley, PA, USA
    Arch Intern Med 164:1192-6. 2004
    ..When induced by benzocaine anesthetic spray and other chemicals, it can result in cyanosis and life-threatening complications...
  9. doi request reprint Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014
    Thomas J Moore
    Institute for Safe Medication Practices, Horsham, PA, USA
    Pharmacoepidemiol Drug Saf 25:713-8. 2016
    ..We assessed the completeness of reports the FDA received in 2014...
  10. doi request reprint Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008
    Thomas J Moore
    Institute for Safe Medication Practices, Alexandria, Virginia2Department of Epidemiology and Biostatistics, The George Washington University School of Public Health and Health Services, Washington, DC
    JAMA Intern Med 174:90-5. 2014
    ....
  11. doi request reprint Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs
    Thomas J Moore
    Institute for Safe Medication Practices, Alexandria, Virginia2Department of Epidemiology and Biostatistics, The George Washington University Milken Institute School of Public Health, Washington, DC
    JAMA Intern Med 174:1930-3. 2014
    ..These agents are used to treat Parkinson disease, restless leg syndrome, and hyperprolactinemia...
  12. pmc Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR)
    Thomas J Moore
    The Institute for Safe Medication Practices, Horsham, Pennsylvania, USA
    Semin Thromb Hemost 38:905-7. 2012
    ..3% for VTE associated with thalidomide. The incidence of these hematologic adverse drug events is high and reporting rates are low, and near the lower boundary of the 1 to 15% range seen for other events...
  13. pmc Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration
    Irving Kirsch
    Department of Psychology, University of Hull, Hull, United Kingdom
    PLoS Med 5:e45. 2008
    ..The purpose of this analysis is to establish the relation of baseline severity and antidepressant efficacy using a relevant dataset of published and unpublished clinical trials...
  14. ncbi request reprint Reported adverse drug events in infants and children under 2 years of age
    Thomas J Moore
    Center for Health Services Research and Policy, George Washington University School of Public Health and Health Services, Washington, DC 20006, USA
    Pediatrics 110:e53. 2002
    ..To characterize risks to infants and young children from drugs and biological products that were identified in spontaneous adverse event reports submitted to the US Food and Drug Administration...